Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional))

Trial Profile

A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assigned to Active Surveillance who are at High Risk for Disease Progression (followed by an Open Label Extension with a Repeat Injection (Optional))

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors LIDDS
  • Most Recent Events

    • 06 Feb 2019 According to a LIDDS media release, Dr. Charlotta Gauffin, Head of Clinical Development, will join the company in March 2019 and will be responsible for this study.
    • 21 Nov 2018 According to a LIDDS media release, in order to further improve the inclusion rate in Part II of this study, company adds two major university clinics (The National Cancer Institute in Vilnius and the University Clinic of Kaunas ) in Lithuania. These sites are now ready to start inclusion of patients
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top